The Experts below are selected from a list of 76914 Experts worldwide ranked by ideXlab platform
Michael Drummond - One of the best experts on this subject based on the ideXlab platform.
-
Economic Evaluation of Medical Devices
Oxford Research Encyclopedia of Economics and Finance, 2018Co-Authors: Michael Drummond, Rosanna Tarricone, Aleksandra TorbicaAbstract:There are a number of challenges in the Economic Evaluation of medical devices (MDs). They are typically less regulated than pharmaceuticals, and the clinical evidence requirements for market authorization are generally lower. There are also specific characteristics of MDs, such as the device–user interaction (learning curve), the incremental nature of innovation, the dynamic nature of pricing, and the broader organizational impact. Therefore, a number of initiatives need to be taken in order to facilitate the Economic Evaluation of MDs. First, the regulatory processes for MDs need to be strengthened and more closely aligned to the needs of Economic Evaluation. Second, the methods of Economic Evaluation need to be enhanced by improving the analysis of the available clinical data, establishing high-quality clinical registries, and better recognizing MDs’ specific characteristics. Third, the market entry and diffusion of MDs need to be better managed by understanding the key influences on MD diffusion and linking diffusion with cost-effectiveness evidence through the use of performance-based risksharing arrangements.
-
consolidated health Economic Evaluation reporting standards cheers statement
BMC Medicine, 2013Co-Authors: Don Husereau, Michael Drummond, Stavros Petrou, Chris Carswell, David Moher, Dan Greenberg, Federico Augustovski, Andrew Briggs, Josephine MauskopfAbstract:Economic Evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate and update previous health Economic Evaluation guidelines efforts into one current, useful reporting guidance. The primary audiences for the CHEERS statement are researchers reporting Economic Evaluations and the editors and peer reviewers assessing them for publication.
-
Health Economic Evaluation: important principles and methodology.
Laryngoscope, 2013Co-Authors: Luke Rudmik, Michael DrummondAbstract:Objectives/Hypothesis To discuss health Economic Evaluation and improve the understanding of common methodology. Results This article discusses the methodology for the following types of Economic Evaluations: cost-minimization, cost-effectiveness, cost-utility, cost-benefit, and Economic modeling. Topics include health-state utility measures, the quality-adjusted life year (QALY), uncertainty analysis, discounting, decision tree analysis, and Markov modeling. Conclusion Economic Evaluation is the comparative analysis of alternative courses of action in terms of both their costs and consequences. With increasing health care expenditure and limited resources, it is important for physicians to consider the Economic impact of their interventions. Understanding common methodology involved in health Economic Evaluation will improve critical appraisal of the literature and optimize future Economic Evaluations.
-
Economic Evaluation for devices and drugs same or different
Value in Health, 2009Co-Authors: Michael Drummond, Adrian Griffin, Rosanna TarriconeAbstract:Although the general methods of Economic Evaluation are well established [1,2], it is often their detailed application that raises methodological challenges. Most international guidelines for Economic Evaluation, although appearing to be generic, have been written with pharmaceuticals in mind [3]. For example, they typically assume that randomized controlled trials (RCTs) will be available for the assessment of relative treatment effect. In this article, we argue that the Economic Evaluation of devices raises additional challenges that international guidelines frequently overlook.
-
Economic Evaluation in health care merging theory with practice
2002Co-Authors: Michael Drummond, Alistair McguireAbstract:To accompany the hugely sccessful 'Methods for Economic Evaluation of Health Care Programmes 2e', this book is a thorough and rigorous discussion of the methodological principles and recent advances in the rapidly advancing field of theory and practice of Economic Evaluation in health care. Written by an internationally acclaimed group of authors, the book provides an in-depth discussion of the latest theoretical advances and gives comprehensive reviews of the available literature. The book covers the main areas of Economic Evaluation, including the methods for measuring costs and outcomes, the collection of data alongside clinical studies, ways of handling uncertainty, discounting and issues relating to the transferability of Economic data.
Eric Mast - One of the best experts on this subject based on the ideXlab platform.
-
Economic Evaluation of Vaccination Programmes
PharmacoEconomics, 2002Co-Authors: Philippe Beutels, Henry A. Glick, Fernando Antoñanzas, W. John Edmunds, G. Ardine Wit, David Evans, Rachel Feilden, A. Mark Fendrick, Gary M. Ginsberg, Eric MastAbstract:The methods that have been used to estimate the clinical and Economic impact of vaccination programmes are not always uniform, which makes it difficult to compare results between Economic analyses. Furthermore, the relative efficiency of vaccination programmes can be sensitive to some of the more controversial aspects covered by general guidelines for the Economic Evaluation of healthcare programmes, such as discounting of health gains and the treatment of future unrelated costs. In view of this, we interpret some aspects of these guidelines with respect to vaccination and offer recommendations for future analyses. These recommendations include more transparency and validation, more careful choice of models (tailored to the infection and the target groups), more extensive sensitivity analyses, and for all Economic Evaluations (also nonvaccine related) to be in better accordance with general guidelines. We use these recommendations to interpret the evidence provided by Economic Evaluation applied to viral hepatitis vaccination. We conclude that universal hepatitis B vaccination (of neonates, infants or adolescents) seems to be the most optimal strategy worldwide, except in the few areas of very low endemicity, where the evidence to enable a choice between selective and universal vaccination remains inconclusive. While targeted hepatitis A vaccination seems Economically unattractive, universal hepatitis A vaccination strategies have not yet been sufficiently investigated to draw general conclusions.
Philippe Beutels - One of the best experts on this subject based on the ideXlab platform.
-
Economic Evaluation of Vaccination Programmes
PharmacoEconomics, 2002Co-Authors: Philippe Beutels, Henry A. Glick, Fernando Antoñanzas, W. John Edmunds, G. Ardine Wit, David Evans, Rachel Feilden, A. Mark Fendrick, Gary M. Ginsberg, Eric MastAbstract:The methods that have been used to estimate the clinical and Economic impact of vaccination programmes are not always uniform, which makes it difficult to compare results between Economic analyses. Furthermore, the relative efficiency of vaccination programmes can be sensitive to some of the more controversial aspects covered by general guidelines for the Economic Evaluation of healthcare programmes, such as discounting of health gains and the treatment of future unrelated costs. In view of this, we interpret some aspects of these guidelines with respect to vaccination and offer recommendations for future analyses. These recommendations include more transparency and validation, more careful choice of models (tailored to the infection and the target groups), more extensive sensitivity analyses, and for all Economic Evaluations (also nonvaccine related) to be in better accordance with general guidelines. We use these recommendations to interpret the evidence provided by Economic Evaluation applied to viral hepatitis vaccination. We conclude that universal hepatitis B vaccination (of neonates, infants or adolescents) seems to be the most optimal strategy worldwide, except in the few areas of very low endemicity, where the evidence to enable a choice between selective and universal vaccination remains inconclusive. While targeted hepatitis A vaccination seems Economically unattractive, universal hepatitis A vaccination strategies have not yet been sufficiently investigated to draw general conclusions.
Weidong Wang - One of the best experts on this subject based on the ideXlab platform.
-
Research on Economic Evaluation Methodology for Radio Spectrum Resource Management
2009 International Conference on Management and Service Science, 2009Co-Authors: Qizhu Song, Weidong WangAbstract:The radio spectrum is a key and rare resource, and Economic mechanisms have been begin to play an important role in radio spectrum resource management in China., the Economic Evaluation on radio spectrum applicants will provide an important reference for radio spectrum managers who make decisions based on Economic mechanisms. On the basis of the analysis on the Economic value of the radio spectrum resource, the Economic Evaluation indexes and their normalized methods are proposed, moreover, the weights for the Economic Evaluation indexes are computed based on the Analytic Hierarchy Process. Finally, the application examples are given, which explain how to make use of the methodology to evaluate the spectrum applicants and analyze the Economic Evaluation results from the different judge matrixes. Keywords-radio spectrum; Economic assessment; Evaluation indexes.
-
Research on Economic Evaluation Methodology for Radio Spectrum Resource Management
2009 International Conference on Management and Service Science, 2009Co-Authors: Qizhu Song, Weidong WangAbstract:The radio spectrum is a key and rare resource, and Economic mechanisms have been begin to play an important role in radio spectrum resource management in China., the Economic Evaluation on radio spectrum applicants will provide an important reference for radio spectrum managers who make decisions based on Economic mechanisms. On the basis of the analysis on the Economic value of the radio spectrum resource, the Economic Evaluation indexes and their normalized methods are proposed, moreover, the weights for the Economic Evaluation indexes are computed based on the Analytic Hierarchy Process. Finally, the application examples are given, which explain how to make use of the methodology to evaluate the spectrum applicants and analyze the Economic Evaluation results from the different judge matrixes.
Rosanna Tarricone - One of the best experts on this subject based on the ideXlab platform.
-
Economic Evaluation of Medical Devices
Oxford Research Encyclopedia of Economics and Finance, 2018Co-Authors: Michael Drummond, Rosanna Tarricone, Aleksandra TorbicaAbstract:There are a number of challenges in the Economic Evaluation of medical devices (MDs). They are typically less regulated than pharmaceuticals, and the clinical evidence requirements for market authorization are generally lower. There are also specific characteristics of MDs, such as the device–user interaction (learning curve), the incremental nature of innovation, the dynamic nature of pricing, and the broader organizational impact. Therefore, a number of initiatives need to be taken in order to facilitate the Economic Evaluation of MDs. First, the regulatory processes for MDs need to be strengthened and more closely aligned to the needs of Economic Evaluation. Second, the methods of Economic Evaluation need to be enhanced by improving the analysis of the available clinical data, establishing high-quality clinical registries, and better recognizing MDs’ specific characteristics. Third, the market entry and diffusion of MDs need to be better managed by understanding the key influences on MD diffusion and linking diffusion with cost-effectiveness evidence through the use of performance-based risksharing arrangements.
-
Economic Evaluation for devices and drugs same or different
Value in Health, 2009Co-Authors: Michael Drummond, Adrian Griffin, Rosanna TarriconeAbstract:Although the general methods of Economic Evaluation are well established [1,2], it is often their detailed application that raises methodological challenges. Most international guidelines for Economic Evaluation, although appearing to be generic, have been written with pharmaceuticals in mind [3]. For example, they typically assume that randomized controlled trials (RCTs) will be available for the assessment of relative treatment effect. In this article, we argue that the Economic Evaluation of devices raises additional challenges that international guidelines frequently overlook.
